DexCom, Inc. (DXCM): Price and Financial Metrics
DexCom, Inc. (DXCM)
Today's Latest Price: $407.35 USD
Updated Jul 2 4:00pm
Add DXCM to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 132 in Medical - Devices & Equipment
See all "A" rated Strong Buy stocks
DXCM Stock Summary
- DXCM has a higher market value than 95.08% of US stocks; more precisely, its current market capitalization is $37,436,613,541.
- With a price/earnings ratio of 253.12, Dexcom Inc P/E ratio is greater than that of about 98.4% of stocks in our set with positive earnings.
- The price/operating cash flow metric for Dexcom Inc is higher than 97.48% of stocks in our set with a positive cash flow.
- If you're looking for stocks that are quantitatively similar to Dexcom Inc, a group of peers worth examining would be SQ, BMRN, IAC, ANSS, and ILMN.
- DXCM's SEC filings can be seen here. And to visit Dexcom Inc's official web site, go to www.dexcom.com.
DXCM Stock Price Chart Technical Analysis Charts
DXCM Price/Volume Stats
| Current price | $407.35 | 52-week high | $428.59 |
| Prev. close | $400.21 | 52-week low | $138.28 |
| Day low | $398.06 | Volume | 1,082,126 |
| Day high | $415.47 | Avg. volume | 1,496,501 |
| 50-day MA | $381.73 | Dividend yield | N/A |
| 200-day MA | $261.50 | Market Cap | 37.62B |
DexCom, Inc. (DXCM) Company Bio
DexCom focuses on the design, development, and commercialization of continuous glucose monitoring systems for patients with diabetes. The company was founded in 1999 and is based in San Diego, California.
DXCM Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $407.35 | $202.14 | -47% |
Below please find a table outlining a discounted cash flow forecast for DXCM, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Dexcom Inc ranked in the 32th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 47%. As for the metrics that stood out in our discounted cash flow analysis of Dexcom Inc, consider:
- The compound growth rate in the free cash flow of Dexcom Inc over the past 5.48 years is 0.77%; that's better than 84.57% of cash flow producing equities in the Healthcare sector, where it is classified.
- 97% of the company's capital comes from equity, which is greater than 89.85% of stocks in our cash flow based forecasting set.
- The business' balance sheet reveals debt to be 3% of the company's capital (with equity being the remaining amount). Approximately merely 10.11% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -48% |
| 1% | -48% |
| 2% | -47% |
| 3% | -47% |
| 4% | -46% |
| 5% | -46% |
Want more companies with a valuation profile/forecast similar to that of Dexcom Inc? See XRAY, CAH, BIO, JNJ, and PDEX.
Loading social stream, please wait...